Nucelis, the microbial strain development subsidiary of agriculture biotech company Cibus, today announced a partnership agreement with Nanjing Darwingenetech Co, Ltd (Darwin) to jointly identify and enter into agreements with China based customers for Nucelis’ proprietary gene-editing and advanced fermentation expertise to improve fermentation yields and reduce costs.
In collaboration with this partnership with Darwin, Nucelis also finalized the signing of its first customer agreement. Financial terms of the agreement were not disclosed.
“We are pleased to be business development partners with Nucelis and to have signed our first customer agreement,” says Jim Xu, President of Darwin and Chairman of Jiangsu Zenji Pharmaceuticals Ltd.
Jack He, Senior Manager of Darwin, adds: “Nucelis has a very valuable and differentiated portfolio of technology and services to assist Chinese manufacturers of food ingredients, animal feed, and other products made via fermentation.”
“We are delighted to partner with Darwin as we build our business in China, where we see a large and growing opportunity in the world’s largest market for products made using fermentation,” says Sean O’Connor, PhD, president and CEO of Nucelis. “Our innovative and proprietary strain development and fermentation expertise are an ideal fit for potential customers in the region, as evidenced by the signing of our first customer agreement.”
